Results 71 to 80 of about 28,228 (226)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

MODERN POSSIBILITIES OF ACHIEVING TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS IN OUTPATIENT PRACTICE: THE LEADER STUDY RESULTS

Рациональная фармакотерапия в кардиологии, 2018
Aim. To study the efficacy and safety of the use of hydrochlorothiazide/losartan or amlodipine/losartan fixed combinations in patients with arterial hypertension (HT) in real clinical practice.Material and methods.
D. V. Nebieridze, A. S. Safaryan, V. A. Vygodin, O. M. Drapkina, S. A. Boytsov   +4 more
doaj   +1 more source

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial

Journal of Cachexia, Sarcopenia and Muscle, Volume 16, Issue 2, April 2025.
ABSTRACT Background Sarcopenia is a progressive muscle disorder that may lead to mobility disability. No pharmaceutical interventions are currently available, and treatment relies on physical exercise and nutrition. The aim of SARA‐INT was to investigate whether BIO101 (20‐hydroxyecdysone), an activator of the MAS receptor, is safe and improves muscle ...
Roger A. Fielding, Michael M. Dao, Kevin Cannon, Moise Desvarieux, Sam S. Miller, Michael Paul Gimness, Donald M. Brandon, Dennis T. Villareal, Olivier Bruyere, Ivan Bautmans, Kyle Rickner, Robert Perry, Stephen B. Kritchevsky, Nicolas Musi, Joe M. Chehade, Judith L. Kirstein, Evelien Gielen, Paul Pickrell, Pierre Dilda, Rene Lafont, Carole Margalef, Yves Rolland, Susanna Del Signore, Jean Mariani, Samuel Agus, Cendrine Tourette, Waly Dioh, Rob van Maanen, Stanislas Veillet   +28 more
wiley   +1 more source

A Practical Analysis Procedure on Generalizing Comparative Effectiveness in the Randomized Clinical Trial to the Real-world Trialeligible Population [PDF]

arXiv
When evaluating the effectiveness of a drug, a Randomized Controlled Trial (RCT) is often considered the gold standard due to its perfect randomization. While RCT assures strong internal validity, its restricted external validity poses challenges in extending treatment effects to the broader real-world population due to possible heterogeneity in ...
arxiv  

Pharmacokinetics of Hydrochlorothiazide, Losartan and E3174 after Oral Doses of Losartan and Losartan/Hydrochlorothiazide in Healthy Chinese Male Volunteers

Pharmacology & Pharmacy, 2012
Aims: A simple and highly sensitive LC-MS method was used to determine the concentrations of losartan, its major active metabolite E3174 and hydrochlorothiazide in human plasma and pharmacokinetic characteristics and metabolism phenotype observation after administration of losartan tablets and losartan/hydrochlorothiazide combination tablets.
Sha Liu, Guiyan Yuan, Chunmin Wei, Benjie Wang, Fanlong Bu, Ruichen Guo   +5 more
openaire   +3 more sources

Semiparametric Joint Modeling to Estimate the Treatment Effect on a Longitudinal Surrogate with Application to Chronic Kidney Disease Trials [PDF]

arXiv
In clinical trials where long follow-up is required to measure the primary outcome of interest, there is substantial interest in using an accepted surrogate outcome that can be measured earlier in time or with less cost to estimate a treatment effect.
arxiv  

Pharmaceutical‐Related Poisonings in Greenland

Basic &Clinical Pharmacology &Toxicology, Volume 136, Issue 4, April 2025.
ABSTRACT The Danish Poison Information Centre (DPIC) received 1827 enquiries from Greenland in the period 2007–2022. The risk and the treatment of poisonings in Greenland are potentially different from those in Denmark. The use and availability of medicines, the ethnicity and the vicinity of health care are different in Greenland compared with Denmark.
Kim Dalhoff, Johanne Mølby Hansen, Søren Bøgevig, Tonny S. Petersen   +3 more
wiley   +1 more source

Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan [PDF]

, 1992
Hiroshi Azuma, Yasunari Niimi, Hidehisa Hamasaki   +2 more
openalex   +1 more source

Sleep characteristics and self‐reported sleep quality in the oldest‐old: Results from a prospective longitudinal cohort study

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Little is known about the correlation between subjective perception and objective measures of sleep quality in particular in the oldest‐old. The aim of this study was to perform longitudinal home sleep monitoring in this age group, and to correlate results with self‐reported sleep quality.
Hugo Saner, Kevin Möri, Narayan Schütz, Philipp Buluschek, Tobias Nef   +4 more
wiley   +1 more source

An unusual case of reagent interference in transfusion medicine workup: Pan reactive indirect antiglobulin test caused by commercial saline solution

Transfusion Medicine, Volume 35, Issue 2, Page 192-196, April 2025.
Abstract Background At the regional transfusion service in the Region of Southern Denmark, serological investigations are primarily carried out using column agglutination techniques. This case study examines an unusual instance of reagent interference in pretransfusion testing using column agglutination at the Hospital of Southern Denmark, Aabenraa ...
Martin Tøffner Pedersen, Helle Bach‐Hansen, Kristina Fruerlund Rasmussen, Mark H. Yazer, Ulrik Sprogøe   +4 more
wiley   +1 more source